Claims for Patent: 5,599,822

Summary for Patent: 5,599,822

Title:	Methods for minimizing bone loss
Abstract:	The present invention provides a method for minimizing the bone loss effect of a compound of formula II ##STR1## or a pharmaceutically acceptable salt thereof, wherein said formula II compound is administered to a mammal in need of treatment, comprising concurrently or sequentially administering to said mammal an effective amount of a compound of formula I ##STR2##
Inventor(s):	Cullinan; George J. (Trafalgar, IN), Fontana; Steven A. (Martinsville, IN)
Assignee:	Eli Lilly and Company (Indianapolis, IN)
Application Number:	08/467,475
Patent Claims:	1. A method for minimizing the bone loss effect of a compound of formula II ##STR6## or a pharmaceutically acceptable salt thereof, wherein said formula II compound is administered to a mammal in need of treatment, comprising concurrently administering to said mammal an effective amount of a compound of formula I ##STR7## wherein each R.sup.1 is independently --OH, --CH.sub.3, --OCOC.sub.6 H.sub.5, or --OCO(C.sub.1 -C.sub.6 alkyl); and R.sup.2 is 1-piperidinyl, 1-pyrrolidinyl, or 1-hexamethyleneimino; or a pharmaceutically acceptable salt thereof. 2. A method according to claim 1 wherein each R.sup.1 is --OH, and R.sup.2 is 1-piperidinyl, or a pharmaceutically acceptable salt thereof. 3. A method according to claim 2 wherein said mammal in need of treatment of a compound of formula I is a human female. 4. A method according to claim 3 wherein said female is suffering from endometriosis. 5. A method for minimizing bone loss comprising the method of claim 1 and further comprising administering to said mammal an effective amount of a bone anabolic agent. 6. A method according to claim 5 wherein each R.sup.1 is --OH, R.sup.2 is 1-piperidinyl, or a pharmaceutically acceptable salt thereof, and said bone anabolic agent is parathyroid hormone (1-84) or (1-34). 7. A method according to claim 6 wherein said mammal in need of treatment of a compound of formula I is a human female. 8. A method according to claim 7 wherein said female is suffering from endometriosis. 9. A pharmaceutical composition comprising a compound of formula II ##STR8## or a pharmaceutically acceptable salt thereof, a compound of formula I ##STR9## wherein each R.sup.1 is independently --OH, --CH.sub.3, --OCOC.sub.6 H.sub.5, or --OCO (C.sub.1 -C.sub.6 alkyl; and R.sup.2 is 1-piperidinyl, 1-pyrrolidinyl, or 1-hexamethyleneimino; or a pharmaceutically acceptable salt thereof; and optionally, a bone anabolic agent, in combination with a pharmaceutically acceptable carrier, diluent, or excipient. 10. A pharmaceutical composition according to claim 9 wherein each R.sup.1 is --OH, and R.sup.2 is 1-piperidinyl, or a pharmaceutically acceptable salt thereof. 11. A pharmaceutical composition according to claim 10 wherein said optional bone anabolic agent is parathyroid hormone (1-84) or (1-34). 12. A pharmaceutical composition according to claim 10 wherein said composition is used for minimizing bone loss from administration of said formula II compound.

Details for Patent 5,599,822

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2039-02-26